Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of 2-Aminopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.67 |
| ▸ | NOS1 | P29475 | 1/20 | 0.67 |
| ▸ | NOS2 | P35228 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopyridine SCHEMBL27965295 | 1.00 | NOS3 (0.67) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL29593240 | 1.00 | NOS3 (0.67) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL28064312 | 0.91 | NOS3 (0.73) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL5289614 | 0.91 | NOS3 (0.73) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL28885375 | 0.87 | — | — | |
| 2-Aminopyridine SCHEMBL28064310 | 0.84 | NOS3 (0.61) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL8517380 | 0.83 | NOS3 (0.73) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL28270573 | 0.83 | NOS3 (0.73) | NOS3NOS1NOS2PI4KAPI4K2B | |
| Trifluoromethanesulfonic Acid SCHEMBL29772678 | 0.82 | NOS3 (0.59) | NOS3NOS1NOS2PI4KAPI4K2B | |
| 2-Aminopyridine SCHEMBL28348266 | 0.82 | NOS3 (0.80) | NOS3NOS1NOS2PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| CN-109475631-A | For targeting the method and composition of the anti-cancer therapies of MENA protein isoform kinases | 迈特斯泰公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-103221415-B | Oxazolo [5,4-b ] pyridin-5-yl compounds and their use for the treatment of cancer | LILLY CO ELI | 2015-06-17 | — | — | CN | disclosed |
| CN-103221415-A | Oxazolo [5,4-b ] pyridin-5-yl compounds and their use for the treatment of cancer | LILLY CO ELI | 2013-07-24 | — | — | CN | disclosed |